Provectus Therapeutics is pioneering a transformative leap in precision oncology with its Single-Cell AI Drug Screening Test, a next-generation platform that combines microfluidics, high-throughput imaging, and proprietary artificial intelligence to analyse over one million individual cancer cells simultaneously. This test enables researchers and clinicians to decode the complex heterogeneity of tumours at the single-cell level, uncovering hidden drug resistance mechanisms, and predicting optimal drug combinations tailored to each patient’s unique cancer profile.
In collaboration with Allevia Lifesciences, a leading life sciences innovator, Provectus Therapeutics is expanding the reach and scalability of this breakthrough technology. Together, we aim to integrate the platform into global clinical workflows, accelerate drug development pipelines, and make personalized cancer treatment accessible to more patients.
How does it work?
A small sample of your tumor is collected during surgery or a routine biopsy.
Your cancer cells are separated into individual cells and exposed to a wide range of cancer drugs in the lab.
Each cell’s reaction is captured using high-resolution imaging and analyzed by artificial intelligence to determine which drugs are most effective.
A detailed report is sent to your oncologist, showing how your cancer cells responded to each treatment.
Your oncologist uses this data to tailor the most effective treatment plan for your unique cancer profile.
Single-Cell AI Test
---------- -----------
In the fight against cancer, understanding each cell’s story is no longer a luxury, it’s a necessity. Provectus Therapeutics’ Single-Cell AI Drug Screening Test turns complexity into clarity, giving clinicians the power to treat the right cells with the right drugs at the right time.
---------- -----------
"
"
Patient - Frequently Asked Questions
💡 What is Single-Cell AI Drug Screening Test? This is an advanced diagnostic tool that analyses how your individual cancer cells respond to a wide range of drugs, one cell at a time. Using artificial intelligence and single-cell technology, it helps identify the most promising treatment options tailored to your unique tumour profile.
🎯 How can this test improve my treatment options? Instead of relying solely on standard protocols, this test provides personalized insights into which therapies your cancer cells are most sensitive to. That means potentially better outcomes, fewer side effects, and more confidence in your treatment plan.
🧑⚕️ Am I a good candidate for this test? If you have been diagnosed with breast cancer and are exploring treatment options this test may be appropriate. Your oncologist can help determine if it’s right for your situation. To date, this test has been done for breast cancer only. We are in the process of optimizing the test for other cancer types, such as lung cancer.
✅ Can I trust the accuracy of the results? A Spin-off Company from CUHK, Provectus Therapeutics Drug Screening AI Platform , powered by Artificial Intelligence and Microfluidics, achieve high throughput drug screening experiment on over 1 million single cancer cells. Based on the corresponding phenotypic responses, Provectus.AI will predict the optimal treatment (drug combination, dosages and treatment duration) to achieve the best anticancer efficacy.
⏱️ How long does it take to get my results? Results are typically available within 5 business days after your sample is received. Your oncologist will receive a detailed report outlining drug response profiles and recommended therapies.
📍 How do I access this test? This test is available through Allevia Lifesciences, the strategic partner of Provectus Therapeutics. For more information on availability, pricing, and clinical coordination, please contact Allevia Lifesciences directly or speak with your healthcare provider. Your doctor can help determine whether this test is appropriate for your condition and guide you through the next steps.
🧪 Where is the test performed? All testing is conducted by Provectus Therapeutics in Hong Kong Science Park.
⚠️ Disclaimer The Single-Cell AI Drug Screening Test offered by Provectus Therapeutics, in strategic partnership with Allevia Lifesciences, is currently experimental and intended solely for informational and research purposes. It is not a substitute for medical consultations, diagnostic procedures, or treatment decisions made by licensed healthcare professionals. The insights provided in these reports should not be used independently to initiate, modify, or discontinue any treatment plan. Drug response is influenced by a wide range of clinical, genetic, and environmental factors that may not be fully captured by this test. All decisions regarding patient care must be made in consultation with your physician, taking into account your complete medical history and current condition.
Physician - Frequently Asked Questions
📘 Background The Single-Cell AI Drug Screening Test is an experimental platform developed by Provectus Therapeutics to evaluate drug sensitivity at the single-cell level using AI-powered analytics. It is designed to support clinical decision-making by identifying which therapies may be most effective for individual patients based on direct ex vivo drug exposure.
💡 What is Single-Cell AI Drug Screening Test? This test exposes dissociated tumour cells to a panel of therapeutic agents and uses high-content imaging and AI algorithms to assess cellular response patterns. The goal is to generate a personalized drug sensitivity profile that complements genomic and histopathological data.
🧪 How is the test performed? Fresh tumour tissue is dissociated into single cells and cultured in a 96-well microplate format. Each well contains a different drug or drug combination. After incubation, cellular responses are measured using imaging-based phenotypic assays, and analysed by proprietary AI models to determine drug efficacy.
💡 What is the clinical advantage of the test? Unlike genomic profiling alone, this test provides functional, real-time data on how live tumour cells respond to drugs. It can help identify non-obvious therapeutic options, guide treatment in refractory cases, and reduce trial-and-error prescribing.
🔬 How does this differ from PDO and NGS Platform? 🧫PDO (Patient-Derived Organoids): Recreates patient-specific tumour biology in 3D culture, supporting personalized drug evaluation and long-term treatment insights. 🧬NGS (Next-Generation Sequencing): Provides actionable genomic data to guide targeted therapies and biomarker-driven clinical decisions. ⚡Single-Cell AI Drug Screening Test: Rapid, direct measurement of how individual cancer cells respond to drugs by testing patient‑derived tumour samples against multiple therapies at the single‑cell level. This enables clinicians to assess functional sensitivity beyond genetic mutations.
👤 Which patients are most appropriate for this test? Patients diagnosed with breast cancer. While useful in refractory, relapsed, or metastatic settings where personalized guidance is critical, it can also be performed alongside NGS at initial diagnosis to provide complementary functional insights helping guide treatment decisions even when genomic data is inconclusive or pending.
📄 What will the report indicate? The report includes: - Drug sensitivity rankings - Phenotypic response scores - AI-derived treatment recommendations - Visual summaries of cellular behaviour It is designed to support but not to replace clinical judgment.
⏱️ When can I expect the results? Results are typically available within 5 business days from sample receipt. A secure digital report is provided to the referring physician.
🧫 What tumour samples can be used? - Fresh surgical or biopsy tissue
📏 What sample size is required Either a minimum of 1 cm³ of tumour tissue or 2-3 core needle biopsies are required. Smaller samples may be accepted but could limit the number of drugs tested.
🧪 Where is the test performed? All testing is conducted by Provectus Therapeutics in Hong Kong Science Park.
⚠️ Disclaimer The Single-Cell AI Drug Screening Test offered by Provectus Therapeutics, in strategic partnership with Allevia Lifesciences, is currently experimental and intended solely for informational and research purposes. It is not a substitute for medical consultations, diagnostic procedures, or treatment decisions made by licensed healthcare professionals. The insights provided in these reports should not be used independently to initiate, modify, or discontinue any treatment plan. Drug response is influenced by a wide range of clinical, genetic, and environmental factors that may not be fully captured by this test. All decisions regarding patient care must be made in consultation with your physician, taking into account your complete medical history and current condition.
